Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
- 1 November 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 380 (9853), 1559-1567
- https://doi.org/10.1016/s0140-6736(12)61428-7
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 yearsHuman Vaccines & Immunotherapeutics, 2012
- Dengue Infection in Children in Ratchaburi, Thailand: A Cohort Study. I. Epidemiology of Symptomatic Acute Dengue Infection in Children, 2006–2009PLoS Neglected Tropical Diseases, 2012
- Population dynamics of DENV-1 genotype V in Brazil is characterized by co-circulation and strain/lineage replacementArchiv für die gesamte Virusforschung, 2012
- The Economic Burden of DengueThe American Journal of Tropical Medicine and Hygiene, 2012
- DengueThe New England Journal of Medicine, 2012
- Dengue Infection in Children in Ratchaburi, Thailand: A Cohort Study. II. Clinical ManifestationsPLoS Neglected Tropical Diseases, 2012
- From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccineVaccine, 2011
- Best Practices in Dengue Surveillance: A Report from the Asia-Pacific and Americas Dengue Prevention BoardsPLoS Neglected Tropical Diseases, 2010
- Emergence of the Asian 1 Genotype of Dengue Virus Serotype 2 in Viet Nam: In Vivo Fitness Advantage and Lineage Replacement in South-East AsiaPLoS Neglected Tropical Diseases, 2010
- The Epidemiology of Dengue in the Americas Over the Last Three Decades: A Worrisome RealityThe American Journal of Tropical Medicine and Hygiene, 2010